Jun. 08 - 11, 2023 | Frankfurt, Germany ehaweb.org
Jun. 13 - 17, 2023 | Lugano, Switzerland icml.ch
Jun. 08 - 11, 2023 | Frankfurt, Germany ehaweb.org
Jun. 13 - 17, 2023 | Lugano, Switzerland icml.ch
T-cell engaging bispecific antibodies in the management of relapsed/refractory follicular lymphoma
Tuesday, 13 June 2023 | 16:30–18:00 CEST
Room B2, Palazzo dei Congressi,
Lugano, Switzerland
What does the future hold for DLBCL treatment and prognosis?
Tuesday 13 June, 2023 | 19:00–20:30 CEST
Room A, Palazzo dei Congressi,
Lugano, Switzerland
heredERA Breast Cancer: A study of giredestrant
+ PH FDC SC vs. PH FDC SC in participants with
HER2-positive, ER-positive LA/mBC heredERA Breast Cancer: A study of giredestrant
+ PH FDC SC vs. PH FDC SC in participants with
HER2-positive, ER-positive LA/mBC
1 minheredERA Breast Cancer: A study of giredestrant
+ PH FDC SC vs. PH FDC SC in participants with
HER2-positive, ER-positive LA/mBC
1 minheredERA Breast Cancer: A study of giredestrant
+ PH FDC SC vs. PH FDC SC in participants with
HER2-positive, ER-positive LA/mBC
heredERA Breast Cancer: A study of giredestrant
+ PH FDC SC vs. PH FDC SC in participants with
HER2-positive, ER-positive LA/mBC
heredERA Breast Cancer: A study of giredestrant
+ PH FDC SC vs. PH FDC SC in participants with
HER2-positive, ER-positive LA/mBCheredERA Breast Cancer: A study of giredestrant
+ PH FDC SC vs. PH FDC SC in participants with
HER2-positive, ER-positive LA/mBC
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.